RIMAG Group released its 2026 interim results for the six months to 30 June, reporting revenue of RMB 513.04 million, a 9.8% increase year-on-year, driven by expansion in lower-tier public hospitals and primary healthcare institutions.

The revenue mix shifted markedly: • Imaging Solution Services surged 40.3% to RMB 227.99 million. • Digital-Intelligent Services more than tripled, up 356.8% to RMB 22.45 million. • Imaging Center Services fell 12.4% to RMB 262.60 million as regulatory and pricing changes pressured the segment.

Gross profit declined 10.4% to RMB 122.91 million; the gross margin narrowed to 24.0% from 29.4% a year earlier, reflecting a larger contribution from lower-margin solution sales and higher R&D spending.

R&D expenses jumped 119.1% to RMB 16.66 million, while administrative costs rose 51.9% to RMB 113.90 million, largely due to RMB 22.51 million of share-based payment charges tied to the 2026 Share Incentive Plan. As a result, RIMAG swung to an IFRS net loss of RMB 27.88 million, compared with a RMB 15.83 million profit in the prior-year period. EBITDA fell 35.9% to RMB 86.85 million; adjusted EBITDA dropped 19.3% to RMB 109.35 million.

Cash and cash equivalents stood at RMB 574.85 million (31 Dec 2025: RMB 623.97 million). Total assets reached RMB 2.98 billion, equity attributable to owners was RMB 1.96 billion, and total borrowings rose to RMB 618.67 million, lifting the gearing ratio to 31.6% (31 Dec 2025: 26.1%).

Operating cash outflow was RMB 4.86 million versus an inflow of RMB 96.78 million a year earlier, reflecting higher working-capital needs, R&D and marketing spend. Capital expenditure totalled RMB 77.6 million, chiefly for imaging equipment and software.

Strategic initiatives included the RMB 14.07 million acquisition of Imaging Ledmar Services & Diagnostics, expanding RIMAG’s footprint into Central and Eastern Europe and Western Asia. The company continued to scale its AI-enabled diagnostic portfolio, with 81 AI products deployed across 56 imaging centres and cumulative assisted diagnoses exceeding 5 million cases.

RIMAG repurchased 255,500 H-shares for HKD 1.99 million and its share-award trust bought 4.89 million shares for HKD 35.68 million. A total of 4.02 million options were exercised under the 2026 Share Incentive Plan.

The board did not declare an interim dividend.

Looking ahead, RIMAG plans to deepen professional imaging services, accelerate digital-intelligent revenue, broaden overseas expansion and advance its data governance capabilities while maintaining elevated R&D investment to reinforce long-term competitiveness.